Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
Journal of obesity & metabolic syndrome
January 1, 1970
Donna H Ryan
Journal ArticleReviewHuman Study
Extracted Claims (2)
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
setmelanotide | decrease | obesity | patients with pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin type 1 deficiency, and leptin receptor deficiency | - | has been approved | #1 |
semaglutide 2.4 mg once weekly | decrease | obesity | patients with obesity (body mass index [BMI] ≥30 kg/m²) | - | has been submitted for approval | #2 |
Abstract
There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity-pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin type 1 (an important enzyme in the melanocortin pathway) and leptin receptor deficiency. Setmelanotide marks the first in a personalized medicine approach to obesity. Second, semaglutide 2.4 mg once weekly has been submitted to regulators in the United States and the European Union for approval for patients with obesity (body mass index [BMI] ≥30 kg/m
Study Links
PubMed ID34518444
Related Supplements